SCHEMBL24734992

SCHEMBL24734992

CC(C)(C)OC(=O)CCCCN1CCN(c2ccc3c(c2)CN([C@H]2CCC(=O)NC2=O)C3=O)CC1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 12/20 0.52
▸ ESR1 P03372 5/20 0.52
▸ WIZ O95785 1/20 0.46
▸ IKZF1 Q13422 1/20 0.45
▸ IKZF2 Q9UKS7 4/20 0.45
▸ CSNK1A1 P48729 2/20 0.44
▸ GSPT1 P15170 1/20 0.44
▸ DDB1 Q16531 1/20 0.44
▸ IKZF3 Q9UKT9 1/20 0.44
▸ CHRM2 P08172 1/20 0.43
▸ CHRM4 P08173 1/20 0.43
▸ CHRM5 P08912 1/20 0.43
▸ CHRM1 P11229 1/20 0.43
▸ CHRM3 P20309 1/20 0.43
▸ METAP2 P50579 1/20 0.43
▸ SLC6A3 Q01959 1/20 0.43
▸ TMEM97 Q5BJF2 1/20 0.43
▸ HRH3 Q9Y5N1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29841236 1.00 CRBN (0.52) CRBNESR1WIZIKZF1IKZF2
SCHEMBL30822432 1.00 CRBN (0.52) CRBNESR1WIZIKZF1IKZF2
SCHEMBL30822421 0.99 CRBN (0.53) CRBNESR1WIZIKZF1IKZF2
SCHEMBL24734974 0.98 CRBN (0.51) CRBNESR1WIZIKZF1IKZF2
SCHEMBL25373583 0.93 CRBN (0.50) CRBNESR1WIZIKZF1IKZF2
SCHEMBL30906291 0.93 CRBN (0.54) CRBNESR1IKZF1IKZF2
SCHEMBL24206987 0.90 CRBN (0.54) CRBNESR1WIZIKZF1IKZF2
SCHEMBL25934608 0.89 CRBN (0.51) CRBNESR1WIZIKZF1CSNK1A1
SCHEMBL30493346 0.88 CRBN (0.51) CRBNESR1WIZIKZF1CSNK1A1
SCHEMBL30493241 0.88 CRBN (0.51) CRBNESR1WIZIKZF1CSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11530222-B2 Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders ACCUTAR BIOTECHNOLOGY INC. (US) 2022-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11530222-B2 Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders BTK, LYN, SYK CRBN 692/4885ESR1 3739/4885WIZ 3555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback